CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank33
Studio
Year-over-Year Change

Cash generated from core business operations

Percentile
P33
Within normal range
vs 5Y Ago
-14.4x
Contraction
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
TTM$-75.59M+12.3%
2024$-86.23M-53.9%
2023$-56.03M+49.4%
2022$-110.79M+6.9%
2021$-119.03M-2363.4%
2020$5.26M+103.7%
2019$-140.48M-86.0%
2018$-75.52M-144.3%
2017$170.37M+8484.5%
2016$-2.03M-